We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+6.67%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$3.19B
AUM Growth
-$83.9M
Cap. Flow
-$366M
Cap. Flow %
-11.48%
Top 10 Hldgs %
36.17%
Holding
103
New
17
Increased
19
Reduced
13
Closed
19

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$71.8M
2
CNC icon
Centene
CNC
+$35.1M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$34M
4
GH icon
Guardant Health
GH
+$22.8M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$22.5M

Top Sells

Rank Stock Value
1
PPD
PPD, Inc. Common Stock
PPD
+$41.5M
2
AZN icon
AstraZeneca
AZN
+$33M
3
PODD icon
Insulet
PODD
+$30.9M
4
GILD icon
Gilead Sciences
GILD
+$27.3M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$27.2M

Sector Composition

Rank Sector Weight
1 Healthcare 91.64%
2 Financials 0.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OSH
76
DELISTED
Oak Street Health, Inc.
OSH
$3.94M 0.12%
67,250
– –
DOCS icon
77
Doximity
DOCS
$3.76B
$1.75M 0.05%
+30,000
New +$1.68M
ALNA
78
DELISTED
Allena Pharmaceuticals
ALNA
$370K 0.01%
284,285
– –
ALLO icon
79
CALL
Allogene Therapeutics
ALLO
$649M
– –
-246,000
Closed -$8.68M
ARKK icon
80
PUT
ARK Innovation ETF
ARKK
$5.66B
– –
-258,700
Closed -$31M
DVAX
81
CALL
DELISTED
Dynavax Technologies
DVAX
– –
-500,000
Closed -$4.92M
DXCM icon
82
CALL
DexCom
DXCM
$31.5B
– –
-348,800
Closed -$31.3M
DXCM icon
83
DexCom
DXCM
$31.5B
– –
-225,768
Closed -$20.3M
HRTX icon
84
CALL
Heron Therapeutics
HRTX
$93.9M
– –
-324,100
Closed -$5.25M
IBB icon
85
PUT
iShares Biotechnology ETF
IBB
$9.34B
– –
-408,500
Closed -$61.5M
ICUI icon
86
CALL
ICU Medical
ICUI
$4.21B
– –
-68,800
Closed -$14.1M
ITOS
87
DELISTED
iTeos Therapeutics
ITOS
– –
-232,216
Closed -$7.94M
MDGL icon
88
Madrigal Pharmaceuticals
MDGL
$10.8B
– –
-82,534
Closed -$9.65M
NVAX icon
89
CALL
Novavax
NVAX
$1.2B
– –
-81,000
Closed -$14.7M
PODD icon
90
Insulet
PODD
$11.5B
– –
-118,382
Closed -$30.9M
TERN
91
DELISTED
Terns Pharmaceuticals
TERN
– –
-329,274
Closed -$7.24M
VRTX icon
92
Vertex Pharmaceuticals
VRTX
$121B
– –
-46,889
Closed -$10.1M
XBI icon
93
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.95B
– –
-350,000
Closed -$47.5M
XLV icon
94
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$41.9B
– –
-1,585,000
Closed -$185M
SPRB
95
Spruce Biosciences
SPRB
$118M
– –
-6,528
Closed -$8.13M
CERN
96
DELISTED
Cerner Corp
CERN
– –
-139,569
Closed -$10M
PPD
97
DELISTED
PPD, Inc. Common Stock
PPD
– –
-1,096,492
Closed -$41.5M
1 2 3
4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return

PFM Health Sciences's Q2 2021 Portfolio in Review

As of Q2 2021, PFM Health Sciences held 103 positions worth $3.19B, down 2.6% from $3.27B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

PFM Health Sciences withdrew a net $366M in Q2 2021, closing 19 positions and reducing 13 holdings. Its most notable exit was PPD, Inc. Common Stock, an estimated $41.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 82% a quarter earlier, followed by Financials.

Against the trend, PFM Health Sciences opened a new position in Seagen Inc. Common Stock worth $76.3M.

  • PFM Health Sciences's largest Q2 2021 buy was Seagen Inc. Common Stock: 482,985 shares worth $76.3M.
  • PFM Health Sciences added most to Centene in Q2 2021, an estimated $35.1M increase.
  • PFM Health Sciences's biggest Q2 2021 reduction was AstraZeneca, cutting an estimated $33M.
  • PFM Health Sciences fully exited PPD, Inc. Common Stock in Q2 2021, selling an estimated $41.5M.
  • PFM Health Sciences's ten largest holdings make up 36% of its $3.19B portfolio in Q2 2021.
  • PFM Health Sciences opened 17 new positions and closed 19 in Q2 2021.
  • PFM Health Sciences's portfolio value fell 2.6% quarter-over-quarter to $3.19B.

Based on PFM Health Sciences's 13F filing for Q2 2021, filed 16 Aug 2021.